R-Pharm Group and AbbVie, a global biopharmaceutical R&D company announced a complete transfer of the technologies required for deep localization of the production of Sevoflurane, an inhalation anesthetic. The finished product be produced at R-Pharm Group’s facilities from the substance supplied by AbbVie
As Deputy Chairman of the Moscow regional government – regional minister of investment and innovations, Denis Butsaev, told journalists today, presently the first vast farm in the Volokolamsk district is being constructed.
Cattle is planned to be brought there in autumn, and before the end of the year the farm will be put in operation.
The construction of the milk processing plant will start in autumn, 2017. The investor expects to launch the whole complex in May, 2018.
Biopharmaceutical company AbbVie and Russian pharmaceutical company R-Pharm have announced the start of a project to localize the full production cycle of the inhalation anesthetic Sevorane (Sevoflurane).
Preparations for the full production cycle began in July 2014 at the R-Pharm production facility in Yaroslavl, which is certified for compliance with national Good Manufacturing Practice (GMP) requirements.
The project to launch a full production cycle will involve the purchase of manufacturing equipment, the transfer of technology for the production of the finished dosage form, the transfer of analytical methods for quality control, the training of production specialists and AbbVie laboratory specialists, the development of the first industrial designs and the study of their stability.
The drug is expected to be available on the market in early 2018.
On 18 June, at the St. Petersburg International Economic Forum, Governor Georgy Poltavchenko met with OOO AbbVie Vice-President Alberto Colzi.
According to the Governor’s press Service, at the meeting, the prospects were discussed for co-operation and the possibility of opening in St. Petersburg a production unit of the innovative company AbbVie – a leader on the global pharma market.
Georgy Poltavchenko stressed that the experience of such major companies as AbbVie was very important as an impetus to the pharma industry. As Alberto Colzi noted, the company is operating in three spheres in Russia: organisation and localisation of production, development of scientific and educational co-operation and participation in programmes for improving the quality of life. The AbbVie Vice-President advised of the company’s intentions to expand co-operation with St. Petersburg, including in joint R&D projects with the St. Petersburg Chemical and Pharmaceutical Academy. The company’s plans for the near future include localisation of production of an innovative, highly effective medicine for treating Hepatitis C.
During a press conference with Rossiya Segodnya on March 4, the biopharmaceutical company AbbVie and R-Pharm announced the launch of a joint project that entails the localization of the full-cycle manufacture of the drug Kaletra (lopinavir + ritonavir tablets, 200 + 50 mg), which is used for the treatment of HIV/AIDS in adults.
Full-cycle production (mixing, extrusion, coating the tablets, packaging and quality control) will be carried out at the R-Pharm production plant in Yaroslavl, which is GMP certified. The investment program for the construction of R-Pharm manufacturing facilities in Yaroslavl Region exceeds $300 million. Over $200 million have already been invested.
Company's website: https://www.abbvie.com
Public company ABBV (NYSE)
Contact: Richard A. Gonzalez, Chairman of the Board and Chief Executive Officer
Global biopharmaceutical company.